Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

NCT07311148 is registered in ClinicalTrials.gov with Guangzhou Patronus Biotech Co., Ltd. as lead sponsor.

NCT NCT07311148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
Lead sponsor
Guangzhou Patronus Biotech Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 23, 2025
Completion date
December 31, 2026
Enrollment
840 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster (hz), recombinant zoster vaccine, shingles, vzv